Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CC-Pharming Pays $4.7 Million to be iBio's China Antibody Partner

publication date: Jul 9, 2018

CC-Pharming of Beijing paid $4.7 million to form a joint commercial relationship with Texas' iBio using iBio's plant-based technology to develop and manufacture antibodies. The first product will be a bio-better biosimilar to rituximab, a Roche drug that is used to treat autoimmune diseases and certain cancers. iBio says its plant-based technology cuts costs and reduces time-to-validation compared to the usual animal cell methods. CC-Pharming could add other antibodies at a later date, which would trigger additional payments. More details....

Stock Symbol: (NYSE AMERICAN:IBIO)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China